MFN1 and myocardial infarction: To investigate the contribution of Mfn1-βIIPKC interaction to the pathophysiology of heart failure, we delivered the SAMβA peptide (or its control peptide, TAT) to rats with myocardial infarction-induced heart failure; the peptides were delivered in a sustained fashion at 3 mg per kg per day, using subcutaneously implanted Alzet pumps.